Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing - 2021 World Medical Innovation Forum
Virtual
May 19–21, 2021

Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing

Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing

Friday, May 21, 2021

9:35 AM – 10:00 AM

The dynamics of venture/PE investing and IPOs are fast evolving. What are the drivers – will the number of investors grow will the size of early rounds continue to grow? How is this reflected in GCT target areas, company design, and biotech overall? Do patients benefit from these trends? Is crossover investing a distinct class or a little of both? Why did it emerge and what are the characteristics of the players?  Will SPACs play a role in the growth of the gene and cell therapy industry. What is the role of corporate investment arms eg NVS, Bayer, GV, etc. – has a category killer emerged?  Are we nearing the limit of what the GCT market can absorb or will investment capital continue to grow unabated?

Moderator:
Roger Kitterman
  • VP, Venture, Mass General Brigham
Speakers:
Ellen Hukkelhoven, PhD
  • Managing Director, Perceptive Advisors
Peter Kolchinsky, PhD
  • Founder and Managing Partner, RA Capital Management
Deep Nishar
  • Senior Managing Partner, SoftBank Investment Advisors
Oleg Nodelman
  • Founder & Managing Partner, EcoR1 Capital
  • Q&A

    10:05 AM – 10:20 AM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA